Lumen Bioscience Awarded Federal Funding to Advance Covid-19 Antibody Cocktail through Phase 2 Clinical Evaluation
- Wednesday, October 6, 2021, 7:13
- Finance
- Add a comment
SEATTLE, Oct. 6, 2021 /PRNewswire/ — Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced new development funding from the US Army for its Covid-19 monoclonal antibody drug cocktail. The support is provided by…
About the Author
adminasapcorp has written 41555 stories on this site.